Abstract
LL37-rIb-AMP4 Hybrid Peptide as a Therapy for Systematic Infections of Acinetobacter baumannii, Pseudomonas aeruginosa, Vancomycin-resistant Enterococcus (VRE), and Methicillin-resistant Staphylococcus aureus (MRSA) cells in a mouse model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have